Opioid-sparing analgesia with clonidine versus fentanyl in inguinal hernia repair: a randomized clinical trial
Clinical Snapshot
PICO Framework
| P — Population | Adult patients (including middle-aged and older adults, male and female) undergoing elective inguinal hernioplasty under local anaesthesia with sedation |
| I — Intervention | Clonidine as an adjuvant analgesic/sedative agent (GLC group, n = 69) |
| C — Comparator | Fentanyl as an adjuvant analgesic/sedative agent (GLF group, n = 69) |
| O — Outcomes | Primary: postoperative pain intensity (Visual Analogue Scale, VAS). Secondary: time to first analgesic request, need for rescue analgesia, sedation level (Richmond Agitation-Sedation Scale, RASS), adverse events, and medication costs |
Bottom Line
This single-centre Brazilian RCT of 138 patients undergoing inguinal hernioplasty under local anaesthesia with sedation found clonidine superior to fentanyl across multiple analgesic endpoints: lower postoperative VAS scores (median 0 vs. 2), a 2-hour longer pain-free interval, and a substantially reduced need for rescue analgesia (34.8% vs. 59.4%; NNT ≈ 4). Adverse event rates and costs were comparable. These findings are clinically plausible given clonidine's established alpha-2 agonist mechanisms, which include supraspinal and spinal analgesia, anxiolysis, and opioid-sparing properties. However, significant methodological limitations temper confidence: blinding is not described (critical for a subjective pain outcome), randomisation methods are unreported, follow-up duration is unspecified, and the trial is from a single regional centre. The conflicting 'superiority' versus 'equivalence' trial labelling also raises editorial concerns. For Australian anaesthetists and surgeons, clonidine represents a low-cost, off-label opioid-sparing option consistent with ANZCA multimodal analgesia principles, but adoption should await replication in larger, adequately blinded, multicentre trials before incorporation into routine protocols.
Key Findings
P Value: Primary outcome (VAS): p = 0.019. Sedation (RASS): p = 0.009. Pain-free time: p = 0.001. Rescue analgesia: p = 0.006.
Effect Size: Median VAS difference: −2 points (clonidine superior). Rescue analgesia: 34.8% (clonidine) vs. 59.4% (fentanyl); RR 0.59. Pain-free time: mean difference +2.0 hours in favour of clonidine. Sedation (RASS): mean difference −0.6 (greater sedation with clonidine).
Primary Outcome: Postoperative pain intensity (VAS): Clonidine group median 0 (IQR 0–3) vs. Fentanyl group median 2 (IQR 0–4); Mann-Whitney U = 1864; p = 0.019. Clonidine was superior.
Nnt Or Sensitivity: NNT to avoid one episode of rescue analgesia: approximately 4.1 (calculated from 59.4% vs. 34.8% event rates; ARR = 24.6%; NNT = 1/0.246 ≈ 4.1). RR for rescue analgesia = 0.59 (clonidine vs. fentanyl).
Confidence Interval: Primary outcome (median VAS difference): 95% CI −3.00 to −2.00. CIs for secondary outcomes (RR, mean differences) not fully reported in abstract.
Clinical Application
Clonidine is an established, widely available, and inexpensive alpha-2 adrenergic agonist with a well-characterised safety profile. Its use as a perioperative adjuvant is technically straightforward and does not require specialised equipment. The main clinical considerations are monitoring for bradycardia, hypotension, and excessive sedation, particularly in elderly patients or those with cardiovascular comorbidities. The greater sedation observed (RASS difference −0.6) requires appropriate monitoring infrastructure. Clonidine is available in Australia and listed on the PBS for hypertension (PBS item 2622B and related), though its perioperative analgesic use is off-label and not PBS-subsidised in this indication. TGA approval exists for clonidine as an antihypertensive; anaesthetic adjuvant use falls under accepted off-label clinical practice. Fentanyl is a Schedule 8 controlled drug in all Australian states and territories, subject to strict prescribing and storage regulations, making opioid-sparing strategies particularly attractive from a regulatory and governance perspective. RACGP and ANZCA guidelines support multimodal analgesia and opioid minimisation in perioperative care. Australian day-surgery centres performing inguinal hernia repair under local anaesthesia with sedation — a growing practice — would find these findings directly relevant. Cost implications are likely minimal given clonidine's generic availability. Institutional drug and therapeutics committees should review the evidence before protocol adoption. Adult patients of mixed sex undergoing elective inguinal hernioplasty under local anaesthesia with sedation, particularly in ambulatory or day-surgery settings where opioid minimisation is a clinical priority. Patients with opioid sensitivity, chronic pain, or those in opioid-sparing enhanced recovery pathways may be particularly relevant candidates.
Abstract
PURPOSE: To evaluate the efficacy, safety, and cost of clonidine compared with fentanyl as an adjuvant for analgesia in patients undergoing inguinal hernia repair. METHODS: This randomized superiority trial included 138 patients allocated to fentanyl (GLF) or clonidine (GLC) groups (n = 69 each), undergoing inguinal hernioplasty under local anesthesia with sedation. The primary outcome was postoperative pain intensity assessed by the visual analog scale (VAS). Secondary outcomes included time to first analgesic request, need for rescue analgesia, sedation level (RASS), adverse events, and medication costs. Results were expressed as mean or median differences, or relative risks, with 95% CI. RESULTS: Baseline characteristics were comparable between groups. Clonidine significantly reduced pain intensity compared with fentanyl (median 0 [IQR 0-3] vs. median 2 [IQR 0-4]; Mann-Whitney U = 1864; 95% CI of median difference - 3.00 to - 2.00; p = 0.019). The clonidine group also showed greater sedation (mean difference - 0.6; p = 0.009), longer pain-free time (mean difference 2.0 h; p = 0.001), and lower need for rescue analgesia (34.8% vs. 59.4%; RR 0.59; p = 0.006). Adverse events and costs were similar. The reduced need for rescue analgesia suggests a clinically relevant opioid-sparing effect. CONCLUSION: Clonidine was superior to fentanyl in improving postoperative analgesia, prolonging pain-free duration, and reducing additional analgesic requirements, while maintaining a comparable safety profile and cost.
This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service